$SRRK earnings report

Scholar Rock reports Q3 2026 net loss of $107.2 million as first ISEMBYLD product revenue of $570 thousand is recorded. AlphAI read Scholar Rock Holding's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readSRRK · Q3 2026 · ended 2026-09-30

Scholar Rock reports Q3 2026 net loss of $107.2 million as first ISEMBYLD product revenue of $570 thousand is recorded

→Mixed quarter

The U.S. launch of ISEMBYLD has started and the company reports early demand and a $205 million PRV sale agreement, but product revenue is very small, the quarterly and nine-month net loss widened, and stockholders' equity fell from $245,488 thousand at December 31, 2025 to $168,676 thousand at September 30, 2026.

Revenue
$570K
EPS · GAAP
$(0.81)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Product revenue, net, Q3 2026 (Three Months Ended September 30, 2026)GAAP$570K––
Cost of revenue, Q3 2026GAAP$8K––
Research and development expense, Q3 2026GAAP$54.13M––
Selling, general and administrative expense, Q3 2026GAAP$52.49M––
Total operating expenses, Q3 2026GAAP$106.6M––
Loss from operations, Q3 2026GAAP−$106.1M––
Other income (expense), net, Q3 2026GAAP−$1.18M––
Net loss, Q3 2026GAAP−$107.2M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.81)––
Stock-based compensation included in net loss, Q3 2026GAAP$17.9M––
Stock-based compensation included in research and development expense, Q3 2026GAAP$6.4M––
Stock-based compensation included in selling, general and administrative expense, Q3 2026GAAP$11.5M––
Product revenue, net, nine months 2026 (Nine Months Ended September 30, 2026)GAAP$570K––
Cost of revenue, nine months 2026GAAP$8K––
Research and development expense, nine months 2026GAAP$164.2M––
Selling, general and administrative expense, nine months 2026GAAP$153.4M––
Total operating expenses, nine months 2026GAAP$317.5M––
Loss from operations, nine months 2026GAAP−$317.0M––
Other income (expense), net, nine months 2026GAAP−$5.67M––
Net loss, nine months 2026GAAP−$322.6M––
Net loss per share, basic and diluted, nine months 2026GAAP$(2.48)––
Cash, cash equivalents and marketable securities, September 30, 2026GAAP$413.6M––
Total assets, September 30, 2026GAAP$446.0M––
Total liabilities, September 30, 2026GAAP$277.3M––
Total stockholders' equity, September 30, 2026GAAP$168.7M––

Capital returns

  • The filing reports no share repurchases and no dividends for the quarter or the nine months.
  • Equity financing is not described in the filing. Weighted average common shares outstanding rose from 113,729,850 to 132,372,289 for the quarter, a figure the filing prints but which is excluded from key metrics as a share count.
  • The company states that the Priority Review Voucher sale for $205 million will provide non-dilutive capital to the balance sheet once closed.

What drove it

  • ISEMBYLD was approved by the FDA on September 11, 2026 and shipped to the specialty network within one week of approval, and the company recorded $570 thousand of net product revenue for the quarter.
  • The company states that cost of revenue was immaterial for the quarter and that, prior to FDA approval, product costs were expensed as research and development expense.
  • The company states that a J-code application for an ISEMBYLD-specific J-code was submitted to CMS in September, with the J-code effective April 1, 2027.
  • The company states that initial patients were infused in October 2026 and that it has an alternate fill-finish facility in place for the EMA resubmission, which it describes as the same site that supported the FDA approval.
  • Research and development expense rose from $50,486 thousand to $54,128 thousand for the quarter, and from $161,565 thousand to $164,176 thousand for the nine months. The filing does not state a cause for the change.
  • Selling, general and administrative expense was $52,495 thousand for the quarter, against $53,064 thousand a year earlier, and $153,364 thousand for the nine months, against $131,184 thousand a year earlier. The filing does not state a cause for the nine-month change.

Concerns

  • Net loss widened to $(107,239) thousand from $(102,220) thousand for the quarter, and to $(322,645) thousand from $(286,974) thousand for the nine months.
  • Product revenue of $570 thousand in the quarter is small against total operating expenses of $106,631 thousand for the same quarter.
  • Total stockholders' equity fell from $245,488 thousand at December 31, 2025 to $168,676 thousand at September 30, 2026, while total liabilities rose from $158,784 thousand to $277,296 thousand.
  • Long-term liabilities increased from $103,365 thousand to $197,172 thousand between the two balance sheet dates. The filing does not explain this change.
  • The forward-looking statements section lists dependence on third parties for commercial supply of ISEMBYLD, the need for additional capital on acceptable terms, and whether early demand translates into sustained patient treatment and product revenue.
  • The PRV sale has not closed. Its closing depends on customary conditions, including expiration of the HSR waiting period.

What to watch

  • Closing of the $205 million PRV sale and receipt of the cash, subject to the HSR waiting period.
  • Quarterly ISEMBYLD product revenue and whether early patient and physician demand converts into sustained treatment, as the company frames it.
  • Timing of the ISEMBYLD-specific J-code effective date of April 1, 2027.
  • CHMP opinion on the resubmitted apitegromab MAA, expected in the first half of 2027.
  • PMDA review of the apitegromab JNDA under priority review, which the company says typically targets approximately nine months.
  • SRK-439 Phase 1 topline data, expected by year end 2026, with data sharing planned for early 2027.
  • Operating expense trend, particularly selling, general and administrative expense as the U.S. launch expands.
  • Regulatory engagement on the development path for subcutaneous apitegromab.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities were $413,599 thousand at September 30, 2026, compared with $367,563 thousand at December 31, 2025.
  • Total assets were $445,972 thousand at September 30, 2026, compared with $404,272 thousand at December 31, 2025.
  • Current liabilities were $80,124 thousand at September 30, 2026, compared with $55,419 thousand at December 31, 2025.
  • Long-term liabilities were $197,172 thousand at September 30, 2026, compared with $103,365 thousand at December 31, 2025.
  • Total liabilities were $277,296 thousand at September 30, 2026, compared with $158,784 thousand at December 31, 2025.
  • Total stockholders' equity was $168,676 thousand at September 30, 2026, compared with $245,488 thousand at December 31, 2025.
  • The filing does not print a cash flow statement, operating cash flow or free cash flow for the period.
  • The filing states that the PRV sale for $205 million is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and that cash will be received upon closing.

Analysis

Scholar Rock reports its first quarter of ISEMBYLD sales. Net product revenue was $570 thousand for the quarter ended September 30, 2026, with no revenue in the comparable quarter of 2025. The company states that cost of revenue was immaterial because product costs were expensed as research and development before FDA approval on September 11, 2026. Revenue is therefore very small relative to the cost base, and the filing does not provide a unit, patient or prescription figure to size the launch further.

The loss picture widened. Total operating expenses were $106,631 thousand for the quarter, against $103,550 thousand a year earlier, and the net loss was $(107,239) thousand against $(102,220) thousand. Research and development expense was $54,128 thousand against $50,486 thousand, and selling, general and administrative expense was $52,495 thousand against $53,064 thousand. For the nine months, selling, general and administrative expense was $153,364 thousand against $131,184 thousand, and the nine-month net loss was $(322,645) thousand against $(286,974) thousand. The filing does not give a cause for these movements. Stock-based compensation within net loss was $17.9 million against $18.3 million, with the R&D and SG&A components shown separately in the release.

The balance sheet shows cash, cash equivalents and marketable securities of $413,599 thousand at September 30, 2026, up from $367,563 thousand at December 31, 2025. Over the same interval total liabilities rose from $158,784 thousand to $277,296 thousand, led by long-term liabilities, which moved from $103,365 thousand to $197,172 thousand. Total stockholders' equity fell from $245,488 thousand to $168,676 thousand. The filing does not include a cash flow statement, so operating cash burn for the period cannot be read from these documents.

After quarter-end, the company entered into a definitive agreement to sell its Priority Review Voucher for $205 million. Closing is subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period, and the company describes the cash as non-dilutive capital. Regulatory milestones are set out with timing: a CHMP opinion on the resubmitted EU MAA is expected in the first half of 2027, the Japanese application is under priority review, and SRK-439 topline data are expected by year end 2026.

The filing provides no guidance for revenue, operating expenses or margins, so there is no prior outlook to compare against. The key points for a reader are the early but very small launch revenue, the widened net loss, the drop in equity, and the pending PRV proceeds, which the company has not yet received.

Management, verbatim

The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world's first and only muscle-targeted therapy for children and adults living with SMA.

David L. Hallal, Chairman and Chief Executive Officer

We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.

David L. Hallal, Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year and prior-quarter comparatives for the ISEMBYLD product revenue line in the second quarter of 2026, because the filing does not print a June 30, 2026 balance sheet or a second-quarter income statement.
  • Prior-quarter (June 30, 2026) cash, cash equivalents and marketable securities, total assets, total liabilities and stockholders' equity, because the filing prints only September 30, 2026 and December 31, 2025 balance sheets.
  • Cash flow statement, operating cash flow and free cash flow for the quarter and the nine months.
  • Year-over-year change percentages for any line item, because the filing prints dollar amounts but no percentage changes.
  • Forward guidance for revenue, gross margin, operating expenses or tax rate, because the filing provides none.
  • Segment or geographic revenue breakdown, because the filing reports a single product revenue line.
  • Non-GAAP reconciliation or non-GAAP operating metrics, because the filing does not print them.
  • Explanation from the company for the nine-month increase in selling, general and administrative expense and for the increase in long-term liabilities.
  • Dollar figure for the PRV sale proceeds received to date, since the cash is to be received upon closing and the closing has not occurred.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readSRRK · Second quarter 2026 · ended June 30, 2026

Scholar Rock reported a $109.9 million net loss and no revenue in the second quarter of 2026 while preparing for a potential apitegromab FDA approval by the September 30, 2026 PDUFA date.

→Mixed quarter

The company advanced apitegromab toward a potential FDA decision and expanded its cash position through ATM proceeds, but remained pre-revenue and reported a $109.9 million quarterly net loss.

Revenue
did not record any revenue

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAPdid not record any revenue––
Net lossGAAP$109.9M––
Net loss per common shareGAAP$0.84 per common share––
Research and development expenseGAAP$58.2M––
General and administrative expenseGAAP$50.7M––
Stock-based compensationother$19.7M––
Stock-based compensation in research and development expenseother$7.5M––
Stock-based compensation in general and administrative expenseother$12.2M––
Cash, cash equivalents, and marketable securitiesother$492.1M––
Net cash proceeds from at-the-market programother$62.8M––

What drove it

  • The apitegromab BLA review is advancing with the Catalent Indiana fill-finish facility and a second fill-finish facility, representing two independent paths to an FDA approval decision.
  • The data package for FDA review of the second fill-finish facility has been submitted, and the company stated that ample supply from that facility is available for commercialization upon FDA approval.
  • The company stated that its U.S. Commercial team is prepared to launch apitegromab upon FDA approval.
  • Scholar Rock initiated the Phase 2 FORGE trial of apitegromab in patients with FSHD.
  • Enrollment and dosing in the Phase 2 OPAL study in infants and toddlers with SMA is ongoing.
  • The Phase 1 study of SRK-439 in healthy volunteers is ongoing, with topline data anticipated in late 2026.

Concerns

  • Scholar Rock did not record any revenue for the quarters ended June 30, 2026 and 2025.
  • The company reported a $109.9 million net loss for the quarter ended June 30, 2026.
  • The FDA inspection classification of Catalent Indiana following an April 2026 general site inspection is pending.
  • The EMA is awaiting the FDA inspection classification of Catalent Indiana, and the company plans to provide updated guidance on timing for a CHMP opinion upon alignment with the EMA.
  • The reported cash balance includes $62.8 million in net cash proceeds from the ATM program during the quarter.

What to watch

  • Potential FDA approval of apitegromab by the September 30, 2026 PDUFA date.
  • FDA review of the submitted data package for the second fill-finish facility.
  • FDA inspection classification of Catalent Indiana.
  • Alignment with the EMA on next steps for the apitegromab MAA and updated timing guidance for a CHMP opinion.
  • Enrollment and dosing progress in the Phase 2 OPAL study.
  • Topline data from the Phase 1 SRK-439 study anticipated in late 2026.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities of $492.1 million as of June 30, 2026.
  • Net cash proceeds of $62.8 million from the Company’s at-the-market (ATM) program during the quarter ended June 30, 2026.

Analysis

Scholar Rock remained pre-revenue in the second quarter of 2026, reporting no revenue and a GAAP net loss of $109.9 million. The loss was nearly unchanged from the $110.0 million net loss reported for the quarter ended June 30, 2025, while net loss per common share was $0.84 compared with $0.98 per common share. The financial profile remains centered on funding development activities and launch preparation ahead of a potential apitegromab approval.

Operating expenses reflected continued investment in the lead program and commercial readiness. Research and development expense was $58.2 million compared with $62.4 million in the prior-year quarter, while general and administrative expense was $50.7 million compared with $49.7 million. Total stock-based compensation was $19.7 million compared with $24.4 million, with $7.5 million included in research and development expense and $12.2 million included in general and administrative expense.

The principal business development is the advancing BLA review for apitegromab in SMA. Management stated that the review is progressing through both the Catalent Indiana fill-finish facility and a second fill-finish facility. The company submitted the data package for FDA review of the second facility and stated that ample supply from that facility is available for commercialization upon FDA approval. The key remaining manufacturing-related variable disclosed is the pending FDA inspection classification of Catalent Indiana following an April 2026 general site inspection.

Scholar Rock is also preparing commercially and broadening clinical development. The U.S. Commercial team is prepared to launch apitegromab upon FDA approval, while the company initiated the Phase 2 FORGE study in FSHD and continued enrollment and dosing in the Phase 2 OPAL study in younger SMA patients. Separately, the Phase 1 study of SRK-439 is ongoing, with topline data anticipated in late 2026. The FDA action date of September 30, 2026 is the central near-term milestone, while EMA timing remains contingent on engagement with the agency and the Catalent Indiana inspection classification.

Liquidity was $492.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026. This balance reflected $62.8 million in net cash proceeds from the ATM program during the quarter. The financing supports the stated regulatory, commercial, and clinical objectives, but also shows that the company raised equity capital during a period in which it continued to report no revenue and a substantial quarterly loss.

Management, verbatim

We are on the threshold of securing the world’s first ever regulatory approval of a myostatin inhibitor, which will also be the first ever muscle-targeted treatment for children and adults living with SMA.

David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock

Backed by a strong balance sheet, our Scholar Rock team is ready to usher in the next phase of innovation for the SMA community in the U.S. immediately upon apitegromab approval.

David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Operating income or loss
  • Operating margin
  • Income tax expense or benefit and tax rate
  • Non-GAAP revenue, earnings, EPS, or operating metrics
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt and debt maturities
  • Share repurchases
  • Dividend information
  • Prior-quarter comparisons for reported metrics
  • Segment revenue
  • Financial guidance for revenue, gross margin, operating expenses, or tax rate
  • Prior outlook for comparison with actual results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SRRK earnings dates

When is Scholar Rock Holding's next earnings date?
AlphAI has no date for SRRK yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.